SCHEMBL5544903

SCHEMBL5544903

[CH2]c1ccccc1Oc1c(C)cccc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTR1A P08908 5/20 0.37
SLC6A2 P23975 4/20 0.37
SLC6A4 P31645 2/20 0.37
ACHE P22303 1/20 0.36
HSP90AA1 P07900 1/20 0.35
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
SCN4A P35499 2/20 0.33
SCN8A Q9UQD0 1/20 0.33
CACNA1H O95180 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541956 0.84 MAPT (0.39) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL5535598 0.83 TSHR (0.52) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL9486976 0.82 TSHR (0.56) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL5535897 0.82 KEAP1 (0.44) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL5534722 0.79 CA1 (0.48) TSHRSMN1; SMN2KDM4EL3MBTL1
SCHEMBL7634253 0.77 CA1 (0.38) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL9488030 0.76 KEAP1 (0.49) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL5407662 0.75 KDM4E (0.59) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL28342363 0.75 ALDH1A1 (0.50) TSHRMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL8402947 0.74 TSHR (0.52) TSHRMEN1KMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TSHR 319/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.